Skip to Main Content

Biopharma has suffered some scares this year in Washington, D.C., and on Wall Street, but from a science perspective, the industry has performed admirably, particularly with big advances in cancer immunotherapy and gene therapy.

I pored over spreadsheets, dug deep into medical journals, stared at stock charts, and consulted my beloved dog, Bo, to determine this year’s nominees for best biopharma CEO. There were some hard decisions to make and a few worthy candidates didn’t make the cut, mainly because the bar this year was so high. Congratulations to each of the finalists.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.